Trial Profile

CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary) ; Tazemetostat (Primary)
Indications Adenocarcinoma; Neuroendocrine tumours; Prostate cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms CELLO-1
Sponsors Epizyme; Ipsen Biopharmaceuticals

09 Dec 2024 Status changed from active, no longer recruiting to discontinued.
31 Oct 2024 Planned End Date changed from 30 Sep 2024 to 8 Nov 2024.
31 Oct 2024 Planned primary completion date changed from 30 Sep 2024 to 8 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com